DOCSLIB.ORG

Antifungal Therapy in Children

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antifungal Therapy in Children Provided by Antifungal Therapy in Children Lead contributors: Valerio Cecinati MD, PhD Chiara Guastadisegno, MD Department of Biomedicine in Childhood University of Bari Bari, Italy A. Introduction Progress in the pharmacological development of antifungal agents has enabled the extension of therapeutic indications to many childhood mycoses, particularly invasive fungal infections (IFI) in children with primary or secondary immunodeficiences.1Thanks to the wider spectrum of action, and the expansion of available information about these drugs and their mechanisms of action as well as their pharmacokinetic and toxicity profiles, antifungal agents are now used to treat both common and uncommon invasive infections in immunocompromised children.1 We performed a systematic review of the literature to compile a guide to information on pediatric antifungal treatments. According to their side targets, the principal antifungal drugs are classified as either antifungal agents acting on plasmatic membranes (azoles, polyenes), antifungal agents acting on synthesis of nucleic acids (5-flucytosine), or antifungal agents acting on fungal cell walls (echinocandins). A. References 1Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38 Suppl 1:335-47. B. Azoles Azole antifungal agents are heterocyclic synthetic compounds and are subdivided into 2 groups: imidazoles and triazoles. The imidazoles are an older group consisting of miconazole, ketoconazole, and clotrimazole. The triazoles include fluconazole and itraconazole; the second generation of triazoles includes voriconazole, ravuconazole, and posaconazole. Isavuconazole, albaconazole, and E-1224, a prodrug of ravuconazole, are the 3 main azole antifungal agents currently under development.1 The azoles inhibit the fungal cytochrome 450-dependent lanosterol 14α-demethylase, which catalyzes a late step in ergosterol biosynthesis. The drugs block demethylation of the C-14 of lanosterol, leading to the accumulation of methylated sterols in the fungal cell membrane and depletion of ergosterol. This results in abnormalities in fungal cell membrane permeability, membrane bound enzyme activity, and deregulation of chitin synthesis.2-4 Azoles differ in their affinity for the 14α-demethylase enzyme and this difference is largely responsible for their varying antifungal potency and spectrum of activity.2 Cross- inhibition of several human CYP-dependent enzymes (3A4, 2C9, and 2C19) is responsible for most of the clinical side effects and drug interaction profiles that have been described with this class. Itraconazole and posaconazole act primarily as inhibitors of 3A4 and 2C9 but with little effect on 2C19. Voriconazole acts as both an inhibitor and a substrate on all 3 isoenzymes, providing ample opportunites for drug–drug interactions because of the frequently shared metabolic pathway. Caution should be used when these agents are concurrently administered with most HMG-CoA reductase inhibitors, benzodiazepines, phenytoin, carbamazepine, cyclosporine, tacrolimus, sirolimus, methylprednisolone, buspirone, alfentanil; the dihydropyridine calcium channel blockers verapamil and diltiazem; the sulfonylureas, rifampin, rifabutin, vincristine, busulfan, docetaxel; and the protease inhibitors ritonavir, indinavir, and saquinavir. The triazoles have also been associated with QTc prolongation and coadministration with other agents known to have similar effects (cisapride, terfenadine, astemizole, mizolastine, dofetilide, quinidine, and pimozide among others) should be avoided.5 Page 2 of 27 The triazoles are additionally embryotoxic and teratogenic, and are secreted into breast milk; therefore administration should be avoided when women are pregnant or lactating.5 Three resistance mechanisms have been described in Candida infections; reduced azole accumulation through active efflux, alteration, over-expression of the target lanosterol 14α-demethylase, and mutation in the ergosterol pathway, which allows for the accumulation of less toxic sterols in the presence of azoles.6 Intrinsic non-albicans Candida resistance is commonly associated with the increased use of fluconazole prophylaxis.6 The new triazole antifungals (voriconazole, posaconazole, and ravuconazole) show good activity against fluconazole- and itraconazole-resistant Candida species and moulds.5 B. References 1Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole, and albaconazole. Curr Opin Investig Drugs. 2010;11:165-74. 2 Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery system for antifungal therapy. Med mycol. 2000;38:335-47. 3 De Beule K, Van Gestel J. Pharmacology of itraconazole.Drugs. 2001;61:27-37. 4 Kaya Z, Gursel T, Kocak U, et al.. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer. 2009 ;52:470-5. 5 Thompson GR 3rd, Cadena J, Patterson TF., Overview of antifungal agents. Clin Chest Med. 2009;30:203-15. 6 Zaoutis TE, Benjamin DK, Steinbach WJ., Antifungal treatment in pediatric patients. Drug Resist Updat. 2005;8:235-45. C. The Triazoles C.1 Fluconazole Fluconazole is fungistatic, and its activity is concentration independent. It is available in oral or intravenous forms. The bioavailability of the oral form is approximately 90%. Drug concentrations in the cerebrospinal fluid (CSF) and vitreous humor are around 80% of those found in blood.1 Fluconazole continues to be one of the most frequently prescribed triazoles because of its excellent bioavailability, tolerability, and side-effect profile. More than 80% of the ingested drug is found in the circulation and 60% to 70% is excreted unchanged in the urine, so it is particularly indicated for treatment of fungal urinary infections. Fluconazole is relatively lipophobic and exhibits limited binding to plasma proteins. As a result of these characteristics, it passes into tissue and fluids very rapidly. Oral absorption remains Page 3 of 27 unchanged in patients receiving acid suppressive therapies such as proton pump inhibitors orH2-blockers.2 C. 2.1 Indications for Fluconazole Fluconazole is active against Candida species. with the exception of C. krusei and C. glabrata. There is no appreciable activity against aspergillus, fusarium, pseudoallescheria, or zygomycetes.3 Fluconazole remains the drug of choice in oropharyngeal candidiasis (not C. krusei, C. glabrata), superficial mycoses as in genital candidiasis and tinea capitis. Tinea capitis always requires systemic treatment because topical antifungal agents do not penetrate the hair follicle.4 Fluconazole can be used alone or as part of a combined antifungal treatment against invasive and disseminated candidiasis,5-6 cryptococcosis and cryptococcal meningitis,7 or histoplasmosis. It has been demonstrated that fluconazole prophylaxis for IFI is safe and effective for reducing Candida infections in neutropenic pediatric patients and in those undergoing chemotherapy.8,9 Recent guidelines from the Infectious Diseases Society of America recommend consideration of fluconazole or an echinocandin for empiric therapy in immunocompromised children at high risk of Candida infection. Echinocandin use in patients with moderate-to-severe disease, recent azole exposure, or a high risk of C. glabrata or C. krusei infection is preferred. Fluconazole or an echinocandin is also preferred as the initial therapy for non-neutropenic candidemia, depending on the disease severity and characteristics. The guidelines recommend treatment with an echinocandin or lipid formulation of AMB for most patients with neutropenic candidemia, although fluconazole has been identified as an alternative for less critically ill patients without recent azole exposure.10 C.2.2 Fluconazole Dosages, Side Effects, and Interactions Fluconazole is available as an oral suspension, in tablet form (50, 100, 150, and 200 mg), and as an intravenous formulation (in 200 or 400 mg doses).11 Several reports demonstrated that fluconazole clearance is more rapid in children than in adults.12 The mean plasma half-life was approximately 20 hours in children and30 hours in adults. Page 4 of 27 Therefore, to achieve comparable drug exposure, the daily fluconazole dosage needs to be approximately doubled for children over 3 months to 16 years of age to 6–12 mg/kg/day with respect to the suggested dosage in adults (3–6 mg/kg/day).12 Fluconazole could be administered to children with renal failureif the daily dosages were adapted to the serum creatinine level.13 Generally, fluconazole is well-tolerated by pediatric patients, even if prolonged treatment is necessary. Anorexia, vomiting, diarrhea, and elevated transaminases are the most reported side effects. Skin rash, alopecia, and headache are other side effects that are rarely described. Although fluconazole has substantially limited drug interactions than other triazole compounds, caution remains necessary because of increased serum levels of phenytoin, glipizide, glyburide, warfarin, rifabutin, and cyclosporine. Fluconazole levels are reduced in the presence of rifampin.14 C.3 Itraconazole Itraconazole is a highly protein-bound fungicide with less than 1% available free drug and with a relatively high volume of distribution.15 Hydroxy-itraconazole is the major metabolite with the same antifungal activity as itraconazole. The absorption of oral itraconazole depends on an acidic environment for maximal absorption, and the concomitant administration of H2-receptor
Load more

Recommended publications
  • Oral Candidiasis: a Review
    International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 2, Issue 4, 2010 Review Article ORAL CANDIDIASIS: A REVIEW YUVRAJ SINGH DANGI1, MURARI LAL SONI1, KAMTA PRASAD NAMDEO1 Institute of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur (C.G.) – 49500 Email: [email protected] Received: 13 Jun 2010, Revised and Accepted: 16 July 2010 ABSTRACT Candidiasis, a common opportunistic fungal infection of the oral cavity, may be a cause of discomfort in dental patients. The article reviews common clinical types of candidiasis, its diagnosis current treatment modalities with emphasis on the role of prevention of recurrence in the susceptible dental patient. The dental hygienist can play an important role in education of patients to prevent recurrence. The frequency of invasive fungal infections (IFIs) has increased over the last decade with the rise in at‐risk populations of patients. The morbidity and mortality of IFIs are high and management of these conditions is a great challenge. With the widespread adoption of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non‐albicans Candida, non‐fumigatus Aspergillus and moulds other than Aspergillus have become increasingly recognised causes of invasive diseases. These emerging fungi are characterised by resistance or lower susceptibility to standard antifungal agents. Oral candidiasis is a common fungal infection in patients with an impaired immune system, such as those undergoing chemotherapy for cancer and patients with AIDS. It has a high morbidity amongst the latter group with approximately 85% of patients being infected at some point during the course of their illness. A major predisposing factor in HIV‐infected patients is a decreased CD4 T‐cell count.
    [Show full text]
  • Clinical Biotechnology and Microbiology ISSN: 2575-4750
    Page 47 to 49 Volume 1 • Issue 1 • 2017 Research Article Clinical Biotechnology and Microbiology ISSN: 2575-4750 Aspergillosis: A Highly Infectious Global Mycosis of Human and Animal Mahendra Pal* Narayan Consultancy on Veterinary Public Health and Microbiology, 4 Aangan, Ganesh Dairy Road, Anand-388001, India *Corresponding Author: Mahendra Pal, Narayan Consultancy on Veterinary Public Health and Microbiology, 4 Aangan, Ganesh Dairy Road, Anand-388001, India. Received: June 09, 2017; Published: June 19, 2017 Abstract Aspergillosis is an important opportunistic fungal saprozoonosis of worldwide distribution. The disease is reported in humans and animals including birds, and is caused primarily by Aspergillus fumigatus, a saprobic fungus of ubiquitous distribution. It occurs in aspergillosis are re- sporadic and epidemic form causing significant morbidity and mortality. Globally, over 200,000 cases of invasive ported each year. The source of infection is exogenous and respiratory tract is the chief portal of entry of fungus. A variety of clinical aspergillosis. The pathogen can signs are observed in humans and animals. Direct demonstration of fungal agent in clinical material and its isolation in pure growth be easily isolated on APRM agar. Detailed morphology of fungus is studied in Narayan stain. Numerous antifungal drugs are used in on mycological medium is still considered the gold standard to confirm an unequivocal diagnosis of clinical practice to treat cases of aspergillosis - . Certain high risk groups should use face mask to prevent inhalation of fungal spores from immediate environment. It is recommended that “APRM medium” and “Narayan stain”, which are easy to prepare and less ex including Aspergillus pensive than other stains and media, should be routinely used in microbiology and public health laboratories for the study of fungi consequences of disease.
    [Show full text]
  • Oral Antifungals Month/Year of Review: July 2015 Date of Last
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluation: Oral Antifungals Month/Year of Review: July 2015 Date of Last Review: March 2013 New Drug: isavuconazole (a.k.a. isavunconazonium sulfate) Brand Name (Manufacturer): Cresemba™ (Astellas Pharma US, Inc.) Current Status of PDL Class: See Appendix 1. Dossier Received: Yes1 Research Questions: Is there any new evidence of effectiveness or safety for oral antifungals since the last review that would change current PDL or prior authorization recommendations? Is there evidence of superior clinical cure rates or morbidity rates for invasive aspergillosis and invasive mucormycosis for isavuconazole over currently available oral antifungals? Is there evidence of superior safety or tolerability of isavuconazole over currently available oral antifungals? • Is there evidence of superior effectiveness or safety of isavuconazole for invasive aspergillosis and invasive mucormycosis in specific subpopulations? Conclusions: There is low level evidence that griseofulvin has lower mycological cure rates and higher relapse rates than terbinafine and itraconazole for adult 1 onychomycosis.2 There is high level evidence that terbinafine has more complete cure rates than itraconazole (55% vs. 26%) for adult onychomycosis caused by dermatophyte with similar discontinuation rates for both drugs.2 There is low
    [Show full text]
  • Invasive Trichosporonosis in a Critically Ill ICU Patient: Case Report
    log bio y: O ro p c e i n M A l a c c c i e n s i l s Paradžik et al., Clin Microbiol 2015, 4:4 C Clinical Microbiology: Open Access DOI:10.4172/2327-5073.1000210 ISSN: 2327-5073 Case Report Open Access Invasive Trichosporonosis in a Critically Ill ICU Patient: Case Report Maja Tomić Paradžik1*, Josip Mihić2, Jasminka Kopić3 and Emilija Mlinarić Missoni4 1Clinical Microbiology Department, Institute for Public Health Brod-Posavina County, Slavonski Brod 2Neurosurgery section, Department of Surgery, GH, Slavonski Brod 3Department of Anesthesiology and Intensive Care, GH, Slavonski Brod 4Reference Center for Systemic Mycoses, Croatian National Institute for Public Health, Zagreb *Corresponding author: Maja Tomić Paradžik, MD, Clinical Microbiology Department Institute for Public Health Brod–Posavina County, Vladimira Nazora 2A, Slavonski Brod 35-000, Croatia, Tel: +385-35-444-051; Fax: +385-35-440-244; E-mail: [email protected] Received date: June 12, 2015; Accepted date: July 15, 2015; Published date: July 22, 2015 Copyright: © 2015 Paradžik MT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Introduction Systemic infections caused by said pathogen are, consequently, most common in patients with acute leukemia, granulocytopenia, T. asahii, a yeast from the Basidiomycetes class, is one of life- neutropenia, solid tumors, hemochromatosis, uremia and AIDS or threatening opportunistic pathogens, most prominently for undergoing corticosteroid therapy and chemotherapy [4-6,10]. granulocytopenic and immunocompromised, as well as AIDS, patients [1-5].
    [Show full text]
  • Case Report Pneumocystis Carinii and Trichosporon Beigelii
    Case Report Pneumocystis Carinii and Trichosporon Beigelii Pneumonia following Allogeneic Haemopoeitic Stem Cell Transplantation Shahid Raza1, Parvez Ahmed1, Badshah Khan1, Khalilullah Hashmi1, Sajjad Mirza2, Shahid Ahmed Abbasi2, Masood Anwar2, Iftikhar Hussain3, Chaudhry Altaf2, Muhammad Khalid Kamal1 Armed Forces Bone Marrow Transplant Centre1, Armed Forces Institute of Pathology2, Combined Military Hospital3, Rawalpindi. Abstract cians and adequately trained lab staff since it can be rapidly fatal if left untreated. Trichosporon beigelii is a fungus that Pneumocystis Carinii and Trichosporon beigelii is another rare cause of pneumonia in immunocompromised are opportunistic infections in immunocompromised patients.1 patients. We report a case of a young lady who underwent haemopoeitic stem cell transplantation for relapsed acute Occurrence of both pneumocystis carinii and lymphoblastic leukemia. This 25 years old female devel- Trichosporon beigelii pneumonia in a single patient has not oped fever, dry cough and rapidly progressive dyspnoea been reported in the literature. We report a case of PCP and during post transplant neutropenia and was found to be suf- Trichosporon beigelii pneumonia in a young female who fering from Pneumocystis carinii pneumonia. She was suc- underwent haemopoeitic stem cell transplant for relapsed cessfully treated with Co-trimoxazole. The patient again acute lymphoblastic leukaemia. presented with similar symptoms on day 55 post transplant. This time Trichosporon beigelii was isolated from bron- Case Report choalveolar lavage and she responded to prompt antifungal A 25 years old female was diagnosed with acute therapy. Other complications encountered during the subse- lymphoblastic leukaemia on 29 May 2001. She received quent course were extensive subcutaneous emphysema and remission induction, intensification and cranial irradiation spontaneous pneumothorax that required chest intubation as per UK ALL X protocol.
    [Show full text]
  • A Case of Disseminated Trichosporon Beigelii Infection in a Patient with Myelodysplastic Syndrome After Chemotherapy
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central J Korean Med Sci 2001; 16: 505-8 Copyright � The Korean Academy ISSN 1011-8934 of Medical Sciences A Case of Disseminated Trichosporon beigelii Infection in a Patient with Myelodysplastic Syndrome after Chemotherapy Trichosporonosis is a potentially life-threatening infection with Trichosporon Jong-Chul Kim, Yang Soo Kim, beigelii, the causative agent of white piedra. The systemic infection by this fungus Chul-Sung Park, Jae-Myung Kang, has been most frequently described in immunocompromised hosts with neu- Baek-Nam Kim, Jun-Hee Woo, tropenia. Here, we report the first patient with disseminated infection by T. beigelii Jiso Ryu, Woo Gun Kim in Korea, acquired during a period of severe neutropenia after chemo-therapy for Department of Internal Medicine, University of Ulsan myelodysplastic syndrome. The patient recovered from the infection after an College of Medicine, Seoul, Korea early-intensified treatment with amphotericin B and a rapid neutrophil recovery. Received : 21 June 2000 The disseminated infection by T. beigelii is still rare, however, is an emerging Accepted : 14 August 2000 fatal mycosis in immunocompromised patients with severe neutropenia. Address for correspondence Jun-Hee Woo, M.D. Division of Infectious Diseases, Asan Medical Center, UUCM, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-736, Korea Tel: +82.2-2224-3300, Fax: +82.2-2224-6970 Key Words : Trichosporon; Immunocompromised Host; Myelodysplastic Syndromes; Amphotericin B E-mail: [email protected] INTRODUCTION showed complete clearance of the neoplastic cells and hypo- celluar marrow. The patient’s cytopenia was supported with Trichosporon beigelii is found in soil and occasionally as a part multiple transfusions of red blood cells, platelets, and plasma.
    [Show full text]
  • Fungal Infections
    FUNGAL INFECTIONS SUPERFICIAL MYCOSES DEEP MYCOSES MIXED MYCOSES • Subcutaneous mycoses : important infections • Mycologists and clinicians • Common tropical subcutaneous mycoses • Signs, symptoms, diagnostic methods, therapy • Identify the causative agent • Adequate treatment Clinical classification of Mycoses CUTANEOUS SUBCUTANEOUS OPPORTUNISTIC SYSTEMIC Superficial Chromoblastomycosis Aspergillosis Aspergillosis mycoses Sporotrichosis Candidosis Blastomycosis Tinea Mycetoma Cryptococcosis Candidosis Piedra (eumycotic) Geotrichosis Coccidioidomycosis Candidosis Phaeohyphomycosis Dermatophytosis Zygomycosis Histoplasmosis Fusariosis Cryptococcosis Trichosporonosis Geotrichosis Paracoccidioidomyc osis Zygomycosis Fusariosis Trichosporonosis Sporotrichosis • Deep / subcutaneous mycosis • Sporothrix schenckii • Saprophytic , I.P. : 8-30 days • Geographical distribution Clinical varieties (Sporotrichosis) Cutaneous • Lymphangitic or Pulmonary lymphocutaneous Renal Systemic • Fixed or endemic Bone • Mycetoma like Joint • Cellulitic Meninges Lymphangitic form (Sporotrichosis) • Commonest • Exposed sites • Dermal nodule pustule ulcer sporotrichotic chancre) (Sporotrichosis) (Sporotrichosis) • Draining lymphatic inflamed & swollen • Multiple nodules along lymphatics • New nodules - every few (Sporotrichosis) days • Thin purulent discharge • Chronic - regional lymph nodes swollen - break down • Primary lesion may heal spontaneously • General health - may not be affected (Sporotrichosis) (Sporotrichosis) Fixed/Endemic variety (Sporotrichosis) •
    [Show full text]
  • WO 2013/038197 Al 21 March 2013 (21.03.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/038197 Al 21 March 2013 (21.03.2013) P O P C T (51) International Patent Classification: Geir [NO/NO]; Bj0rndalen 81, N-7072 Heimdal (NO). A01N 43/16 (2006.01) A01N 43/653 (2006.01) MYRVOLD, Rolf [NO/NO]; 0vre Gjellum vei 28, N- A61K 31/734 (2006.01) A01P 3/00 (2006.01) 1389 Heggedal (NO). A01N 43/90 (2006.01) (74) Agent: DEHNS; St Bride's House, 10 Salisbury Square, (21) International Application Number: London EC4Y 8JD (GB). PCT/GB20 12/052274 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date kind of national protection available): AE, AG, AL, AM, 14 September 2012 (14.09.2012) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (25) English Filing Language: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 1116010.8 15 September 201 1 (15.09.201 1) GB NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (71) Applicant (for all designated States except US): AL- RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, GIPHARMA AS [NO/NO]; Industriveien 33, N-1337 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, Sandvika (NO).
    [Show full text]
  • Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
    American Thoracic Society Documents An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients Andrew H. Limper, Kenneth S. Knox, George A. Sarosi, Neil M. Ampel, John E. Bennett, Antonino Catanzaro, Scott F. Davies, William E. Dismukes, Chadi A. Hage, Kieren A. Marr, Christopher H. Mody, John R. Perfect, and David A. Stevens, on behalf of the American Thoracic Society Fungal Working Group THIS OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY (ATS) WAS APPROVED BY THE ATS BOARD OF DIRECTORS, MAY 2010 CONTENTS immune-compromised and critically ill patients, including crypto- coccosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; Introduction and rare and emerging fungal infections. Methods Antifungal Agents: General Considerations Keywords: fungal pneumonia; amphotericin; triazole antifungal; Polyenes echinocandin Triazoles Echinocandins The incidence, diagnosis, and clinical severity of pulmonary Treatment of Fungal Infections fungal infections have dramatically increased in recent years in Histoplasmosis response to a number of factors. Growing numbers of immune- Sporotrichosis compromised patients with malignancy, hematologic disease, Blastomycosis and HIV, as well as those receiving immunosupressive drug Coccidioidomycosis regimens for the management of organ transplantation or Paracoccidioidomycosis autoimmune inflammatory conditions, have significantly con- Cryptococcosis tributed to an increase in the incidence of these infections. Aspergillosis Definitive
    [Show full text]
  • Genetic Diversity and Antifungal Susceptibility Profiles in Causative Agents of Sporotrichosis
    Rodrigues et al. BMC Infectious Diseases 2014, 14:219 http://www.biomedcentral.com/1471-2334/14/219 RESEARCH ARTICLE Open Access Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis Anderson Messias Rodrigues1, G Sybren de Hoog2, Débora de Cássia Pires3, Raimunda Sâmia Nogueira Brihante4, José Júlio da Costa Sidrim4, Marcos Fabio Gadelha5, Arnaldo Lopes Colombo3 and Zoilo Pires de Camargo1* Abstract Background: Sporotrichosis is a chronic subcutaneous mycosis of humans and animals, which is typically acquired by traumatic inoculation of plant material contaminated with Sporothrix propagules, or via animals, mainly felines. Sporothrix infections notably occur in outbreaks, with large epidemics currently taking place in southeastern Brazil and northeastern China. Pathogenic species include Sporothrix brasiliensis, Sporothrix schenckii s. str., Sporothrix globosa, and Sporothrix luriei, which exhibit differing geographical distribution, virulence, and resistance to antifungals. The phylogenetically remote species Sporothrix mexicana also shows a mild pathogenic potential. Methods: We assessed a genetically diverse panel of 68 strains. Susceptibility profiles of medically important Sporothrix species were evaluated by measuring the MICs and MFCs for amphotericin B (AMB), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), posaconazole (PCZ), flucytosine (5FC), and caspofungin (CAS). Haplotype networks were constructed to reveal interspecific divergences within clinical Sporothrix species to evaluate genetically deviant isolates. Results: ITC and PCZ were moderately effective against S. brasiliensis (MIC90 = 2 and 2 μg/mL, respectively) and S. schenckii (MIC90 = 4 and 2 μg/mL, respectively). PCZ also showed low MICs against the rare species S. mexicana. 5FC, CAS, and FLC showed no antifungal activity against any Sporothrix species. The minimum fungicidal concentration ranged from 2 to >16 μg/mL for AMB against S.
    [Show full text]
  • Glucocorticoids and Invasive Fungal Infections
    REVIEW Review Glucocorticoids and invasive fungal infections Michail S Lionakis and Dimitrios P Kontoyiannis Since the 1990s, opportunistic fungal infections have emerged as a substantial cause of morbidity and mortality in profoundly immunocompromised patients. Hypercortisolaemic patients, both those with endogenous Cushing’s syndrome and, much more frequently, those receiving exogenous glucocorticoid therapy, are especially at risk of such infections. This vulnerability is attributed to the complex dysregulation of immunity caused by glucocorticoids. We critically review the spectrum and presentation of invasive fungal infections that arise in the setting of hypercortisolism, and the ways in which glucocorticoids contribute to their pathogenesis. A better knowledge of the interplay between glucocorticoid-induced immunosuppression and invasive fungal infections should assist in earlier recognition and treatment of such infections. Efforts to decrease the intensity of glucocorticoid therapy should help to improve outcomes of opportunistic fungal infections. Introduction efficient phagocytic capacity, phagocytosing more than Cushing’s syndrome is a metabolic condition featuring 108 conidia daily.5 Still, some conidia escape phagocytosis, persistently excessive plasma cortisol levels (normal germinate to hyphae, and establish an invasive infection. morning values: 138–607 nmol/L). Its origins fall into two Then, neutrophils are chemotactically attracted and categories. First, endogenous Cushing’s syndrome is attach to the hyphae, which
    [Show full text]
  • Epidemiological Profile and Antifungal Susceptibility Pattern of Trichosporon Species in a Tertiary Care Hospital in Chandigarh, India
    Current Medical Mycology 2021, 7(1): 19-24 Epidemiological profile and antifungal susceptibility pattern of Trichosporon species in a tertiary care hospital in Chandigarh, India Vibha Mehta1, Jagdish Chander1, Neelam Gulati1*, Nidhi Singla1, Hena Vasdeva2, Raman Sardana2, Awadhesh Kumar Pandey3 1 Department of Microbiology, Government Medical College Hospital, Chandigarh, India 2 Department of Microbiology, Indraprastha Apollo Hospitals, New Delhi, India 3 Department of Radiotherapy, Government Medical College Hospital, Chandigarh, India Article Info A B S T R A C T Article type: Background and Purpose: Trichosporon species are ubiquitous in nature which are Original article associated with fatal opportunistic invasive infections, especially in immunocompromised patients. The present study aimed to evaluate the epidemiological and clinical details, as well as the antifungal susceptibility pattern of the patients with Trichosporon infections. Materials and Methods: In total, 50 clinical isolates of Trichosporon species from Article History: various samples were included in this study. The samples were isolated over a period of Received: 20 October 2020 18 months from patients in a tertiary hospital in North India. The isolates were Revised: 22 December 2020 characterised phenotypically with Vitek MS (bioMérieux, France). Trichosporon spp. Accepted: 06 February 2021 were isolated from urine (30%), nail (30%), tissue (16%), pleural fluid (14%), and sputum (5%). In total, majority of the isolates were of Trichosporon asahii (92%), followed by Trichosporon mucoides (6%), and Trichosporon ovoides (2%). It is noteworthy that most of the reported cases were from intensive care unit (34%). * Corresponding author: Results: Intravenous catheters, antibiotics, and antifungal uptake were significantly Neelam Gulati associated risk factors with Trichosporon infection.
    [Show full text]